203 related articles for article (PubMed ID: 32876513)
1. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer.
Bley N; Schott A; Müller S; Misiak D; Lederer M; Fuchs T; Aßmann C; Glaß M; Ihling C; Sinz A; Pazaitis N; Wickenhauser C; Vetter M; Ungurs O; Strauss HG; Thomssen C; Hüttelmaier S
RNA Biol; 2021 Mar; 18(3):391-403. PubMed ID: 32876513
[TBL] [Abstract][Full Text] [Related]
2. Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous activation of MEK1/2 and Src signaling pathways.
Fang D; Chen H; Zhu JY; Wang W; Teng Y; Ding HF; Jing Q; Su SB; Huang S
Oncogene; 2017 Mar; 36(11):1546-1558. PubMed ID: 27617576
[TBL] [Abstract][Full Text] [Related]
3. Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
Simpkins F; Jang K; Yoon H; Hew KE; Kim M; Azzam DJ; Sun J; Zhao D; Ince TA; Liu W; Guo W; Wei Z; Zhang G; Mills GB; Slingerland JM
Clin Cancer Res; 2018 Oct; 24(19):4874-4886. PubMed ID: 29959144
[No Abstract] [Full Text] [Related]
4. SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis.
Zhu Y; Yang L; Wang J; Li Y; Chen Y
J Gynecol Oncol; 2022 Nov; 33(6):e75. PubMed ID: 36245227
[TBL] [Abstract][Full Text] [Related]
5. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo.
Simpkins F; Hevia-Paez P; Sun J; Ullmer W; Gilbert CA; da Silva T; Pedram A; Levin ER; Reis IM; Rabinovich B; Azzam D; Xu XX; Ince TA; Yang JY; Verhaak RG; Lu Y; Mills GB; Slingerland JM
Clin Cancer Res; 2012 Nov; 18(21):5911-23. PubMed ID: 22896656
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma.
Chua KN; Kong LR; Sim WJ; Ng HC; Ong WR; Thiery JP; Huynh H; Goh BC
Oncotarget; 2015 Oct; 6(30):29991-30005. PubMed ID: 26358373
[TBL] [Abstract][Full Text] [Related]
7. Cigarette smoke disrupts the integrity of airway adherens junctions through the aberrant interaction of p120-catenin with the cytoplasmic tail of MUC1.
Zhang L; Gallup M; Zlock L; Basbaum C; Finkbeiner WE; McNamara NA
J Pathol; 2013 Jan; 229(1):74-86. PubMed ID: 22833523
[TBL] [Abstract][Full Text] [Related]
8. SRC-induced disassembly of adherens junctions requires localized phosphorylation and degradation of the rac activator tiam1.
Woodcock SA; Rooney C; Liontos M; Connolly Y; Zoumpourlis V; Whetton AD; Gorgoulis VG; Malliri A
Mol Cell; 2009 Mar; 33(5):639-53. PubMed ID: 19285946
[TBL] [Abstract][Full Text] [Related]
9. M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.
Zeng XY; Xie H; Yuan J; Jiang XY; Yong JH; Zeng D; Dou YY; Xiao SS
Cancer Biol Ther; 2019; 20(7):956-966. PubMed ID: 31062668
[No Abstract] [Full Text] [Related]
10. IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner.
Müller S; Glaß M; Singh AK; Haase J; Bley N; Fuchs T; Lederer M; Dahl A; Huang H; Chen J; Posern G; Hüttelmaier S
Nucleic Acids Res; 2019 Jan; 47(1):375-390. PubMed ID: 30371874
[TBL] [Abstract][Full Text] [Related]
11. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
12. IGF2BP1 promotes mesenchymal cell properties and migration of tumor-derived cells by enhancing the expression of LEF1 and SNAI2 (SLUG).
Zirkel A; Lederer M; Stöhr N; Pazaitis N; Hüttelmaier S
Nucleic Acids Res; 2013 Jul; 41(13):6618-36. PubMed ID: 23677615
[TBL] [Abstract][Full Text] [Related]
13. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer.
Hew KE; Miller PC; El-Ashry D; Sun J; Besser AH; Ince TA; Gu M; Wei Z; Zhang G; Brafford P; Gao W; Lu Y; Mills GB; Slingerland JM; Simpkins F
Clin Cancer Res; 2016 Feb; 22(4):935-47. PubMed ID: 26482043
[TBL] [Abstract][Full Text] [Related]
14. RAB26-dependent autophagy protects adherens junctional integrity in acute lung injury.
Dong W; He B; Qian H; Liu Q; Wang D; Li J; Wei Z; Wang Z; Xu Z; Wu G; Qian G; Wang G
Autophagy; 2018; 14(10):1677-1692. PubMed ID: 29965781
[TBL] [Abstract][Full Text] [Related]
15. Targeting SRC in mucinous ovarian carcinoma.
Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
[TBL] [Abstract][Full Text] [Related]
16. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
17. Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in KRAS-Mutant Lung Cancer.
Kitai H; Ebi H; Tomida S; Floros KV; Kotani H; Adachi Y; Oizumi S; Nishimura M; Faber AC; Yano S
Cancer Discov; 2016 Jul; 6(7):754-69. PubMed ID: 27154822
[TBL] [Abstract][Full Text] [Related]
18. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors.
Müller S; Bley N; Glaß M; Busch B; Rousseau V; Misiak D; Fuchs T; Lederer M; Hüttelmaier S
Nucleic Acids Res; 2018 Jul; 46(12):6285-6303. PubMed ID: 29660014
[TBL] [Abstract][Full Text] [Related]
19. Serotonin/HTR1E signaling blocks chronic stress-promoted progression of ovarian cancer.
Qin X; Li J; Wang S; Lv J; Luan F; Liu Y; Chen Y; Chen X; Zhao Y; Zhu J; Piao Y; Zhang W; Shi Y; Xiang R; Qu P; Wang L
Theranostics; 2021; 11(14):6950-6965. PubMed ID: 34093864
[No Abstract] [Full Text] [Related]
20. mTORC2 deploys the mRNA binding protein IGF2BP1 to regulate c-MYC expression and promote cell survival.
Lambrianidou A; Sereti E; Soupsana K; Komini C; Dimas K; Trangas T
Cell Signal; 2021 Apr; 80():109912. PubMed ID: 33388443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
